Experience of using combined mucoactive drugs in the management of patients with productive cough

Cough is a common symptom of respiratory diseases. The formation of mucus in the respiratory tract and the cough reflex are associated with a physiological protective function. Productive cough in inflammatory diseases is caused by hypersecretion of mucus; which can lead to impaired mucociliary clearance; increased risk of infection; airway occlusion; decreased therapy effectiveness; severe impairment of quality of life; and other complications. The article presents clinical cases of acute bronchitis and exacerbation of chronic obstructive pulmonary disease; demonstrating management tactics; including approaches to antibacterial therapy; as well as the effectiveness of combined mucoactive drugs for productive cough. A clinical case of acute bronchitis demonstrates a cure without the use of antibacterial therapy and the effectiveness of the combined mucolytic drug salbutamol + bromhexine hydrochloride + guaifenesin to relieve productive cough. Using the example of a clinical case of COPD exacerbation; the criteria for prescribing antibacterial therapy; as well as the effectiveness of prescribing a combined mucoactive drug to relieve cough and improve sputum expectoration; are analyzed. The validity and effectiveness of the use of combined mucoactive drugs; given in clinical cases; are compared with domestic and foreign clinical recommendations. The results of clinical studies that have proven the effectiveness of using a fixed combination of salbutamol + bromhexine hydrochloride + guaifenesin for productive cough; as well as improved sputum characteristics compared with other groups of mucolytic drug combinations; are presented.

1. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. https://doi.org/10.1183/13993003.01136-2019.

2. Song WJ, An J, McGarvey L. Recent progress in the management of chronic cough. Korean J Intern Med. 2020;35(4):811–822. https://doi.org/10.3904/kjim.2020.013.

3. Mukae H, Kaneko T, Obase Y, Shinkai M, Katsunuma T, Takeyama K et al. The Japanese respiratory society guidelines for the management of cough and sputum (digest edition). Respir Investig. 2021;59(3):270–290. https://doi.org/10.1016/j.resinv.2021.01.007.

4. Shah BK, Singh B, Wang Y, Xie S, Wang C. Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment. Mediators Inflamm. 2023;2023:8840594. https://doi.org/10.1155/2023/8840594.

5. Martin MJ, Harrison TW. Causes of chronic productive cough: An approach to management. Respir Med. 2015;109(9):1105–1113. https://doi.org/10.1016/j.rmed.2015.05.020.

6. Orlova NV. Management of cough in the review of current guidelines. Meditsinskiy Sovet. 2019;(6):74–81. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-74-81.

7. Orlova NV. Chronic cough: differential diagnosis and treatment. Meditsinskiy Sovet. 2020;(17):124–131. (In Russ.) https://doi.org/10.21518/2079-701X2020-17-124-131.

8. Авдеев СН, Айсанов СН, Ардашева ТВ, Белевский АС, Демко ИВ, Зайцев АА и др. Клинические рекомендации. Хроническая обструктивная болезнь легких. 2023. Режим доступа: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf.

9. Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Respir Res. 2016;3(1):e000137. https://doi.org/10.1136/bmjresp-2016-000137.

10. Butler CC, Hood K, Verheij T, Little P, Melbye H, Nuttall Jet al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ. 2009;338:b2242. https://doi.org/10.1136/bmj.b2242.

11. Arroll B, Kenealy T. Antibiotics for acute bronchitis. BMJ. 2001;322(7292):939–940. https://doi.org/10.1136/bmj.322.7292.939.

12. Zanasi A, Lanata L, Saibene F, Fontana G, Dicpinigaitis PV, Venier V, De Blasio F. Prospective study of the efficacy of antibiotics versus antitussive drugs for the management of URTI-related acute cough in children. Multidiscip Respir Med. 2016;11:29. https://doi.org/10.1186/s40248-016-0059-y.

13. Kardos P, Dinh QT, Fuchs KH, Gillissen A, Klimek L, Koehler M et al. German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. Respir Med. 2020;170:105939. https://doi.org/10.1016/j.rmed.2020.105939.

14. An J, Lee H, Lee J, Kang SY, Yang MS, Song WJ et al. Prescription patterns and symptom relief of antitussives and expectorants in patients with cough: a nationwide study in Korea. J Thorac Dis. 2024;16(9):6150–6160. https://doi.org/10.21037/jtd-23-1744.

15. Bosmann M, Grailer JJ, Zhu K, Matthay MA, Sarma JV, Zetoune FS, Ward PA. Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury. FASEB J. 2012;26(5):2137–2144. https://doi.org/10.1096/fj.11-201640.

16. Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacol Rev. 2020;72(1):218–252. https://doi.org/10.1124/pr.119.018150.

17. Hughes DT. Diseases of the respiratory system: cough suppressants, expectorants, and mucolytic agents. Br Med J. 1978;1(6121):1202–1203. https://doi.org/10.1136/bmj.1.6121.1202.

18. Morice AH, Kantar A, Dicpinigaitis PV, Birring SS, McGarvey LP, Chung KF. Treating acute cough: wet versus dry – have we got the paradigm wrong? ERJ Open Res. 2015;1(2):00055–02015. https://doi.org/10.1183/23120541.00055-2015.

19. Ohar JA, Donohue JF, Spangenthal S. The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review. Chronic Obstr Pulm Dis. 2019;6(4):341–349. https://doi.org/10.15326/jcopdf.6.4.2019.0139.

20. Albrecht HH, Dicpinigaitis PV, Guenin EP. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. Multidiscip Respir Med. 2017;12:31. https://doi.org/10.1186/s40248-017-0113-4.

21. Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respir Res. 2012;13(1):98. https://doi.org/10.1186/1465-9921-13-98.

22. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017;12:7. https://doi.org/10.1186/s40248-017-0088-1.

23. Prabhu Shankar S, Chandrashekharan S, Bolmall CS, Baliga V. Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study. J Indian Med Assoc. 2010;108(5):313–320. Available at: https://pubmed.ncbi.nlm.nih.gov/21121410/.

24. Jayaram S, Desai A. Efficacy and safety of Ascoril expectorant and other cough formula in the treatment of cough management in paediatric and adult patients – a randomised double-blind comparative trial. J Indian Med Assoc. 2000;98(2):68–70. Available at: https://pubmed.ncbi.nlm.nih.gov/11016157/